Clinical trials: Alopecia, Androgenetic
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899)
Evaluate the ability of injections of Ji Gami(TM) and Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451112
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenic Alopecia
Assessment of the Effects and Tolerance of the RV4986A Lotion in Men With AGA After Hair Transplant
Alopecia involves a diminution of visible hair that can have significant psychosocial effects and impairment of quality of life.
- Trial name
- NCT06576492
- Testing
- RV4986A lotion
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Androgenetic Alopecia
Point-of-Care Adipose-derived Cells for Hair Growth
Androgenetic alopecia (AGA) is the most common form of hair loss and affects 50% and 23% of Caucasian men and women, respectively, over the age of 50.
- Trial name
- ASVF-2016 (NCT02729415)
- Testing
- Stromal Vascular Fraction Cells (SVF Cells) Injection, Liposuction, Hair Measurements
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Florida
Alopecia
Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers
The aim of this study is to determine the bioequivalence of 5 x 0.1 milligram (mg) capsules compared to 1 x 0.5 mg capsule of dutasteride in healthy male subjects.
- Trial name
- NCT01929330
- Testing
- GI198745 0.1 mg, GI198745 0.5 mg
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Androgenetic Alopecia (AGA), Androgenetic Alopecia
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA). AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that…
- Conditions
- Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia
- Trial name
- NCT07146022
- Testing
- VDPHL01 QD, VDPHL01 BID
- Where
- 71 sites in United States
- Volunteers
- 552 people
- Sponsor
- Veradermics, Inc.
Hair Loss/Baldness, Androgenic Alopecia
Effect of the Composition From Fish on Promoting Hair Growth
According to the World Health Organization data, one out of every five Chinese men has a hair loss symptom, and the hair loss is as high as 84% before the age of 30.
- Conditions
- Hair Loss/Baldness, Androgenic Alopecia, Male Pattern Baldness, Female Pattern Alopecia
- Trial name
- NCT05450861
- Testing
- SF DNA extraction composition
- Where
- Taiwan
- Volunteers
- 53 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Androgenetic Alopecia
Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration
The goal of this clinical trial is to assess the safety of the AH-001 drug substance at concentrations of 0.2%, 0.5%, 1%, and 2% in healthy volunteers and male subjects with androgenetic alopecia (AGA).
- Trial name
- NCT06927960
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AnHorn Medicines Co. Ltd.
Androgenetic Alopecia
Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
The purpose of this study is to evaluate the effect of using a purified botulinum toxin (Xeomin®, Merz, USA), the same injectable used to improve face wrinkles, to treat a specific type of hair loss seen in men and women not…
- Trial name
- NCT05456087
- Testing
- incobotulinumtoxin A
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Zel Skin and Laser Specialists
Female Pattern Hair Loss, Androgenetic Alopecia (AGA)
A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss
Pantovigar - a high effective product designed primarily for the treatment of diffuse hair loss in women as well as for the treatment of damaged hair, in the combined therapy can be successfully applied in other types of…
- Conditions
- Female Pattern Hair Loss, Androgenetic Alopecia (AGA), Ludwig Type 1, Ludwig Type 2
- Trial name
- NCT01900041
- Testing
- Pantovigar, Minoxidil 2% only
- Where
- 2 sites in Russia
- Volunteers
- 74 people
- Sponsor
- Merz Pharmaceuticals GmbH
Androgenetic Alopecia, Androgenic Alopecia
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss
To demonstrate that the ALRV5XR multi-molecular targeting treatment regimen of a daily shampoo, conditioner, topical serum and oral supplement is superior to placebo in promoting hair growth as assessed by change in hair density…
- Conditions
- Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair
- Trial name
- REBOOT-MEN (NCT04450589)
- Testing
- ALRV5XR, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Arbor Life Labs
Androgenetic Alopecia (AGA)
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
This study is designed to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.
- Trial name
- NCT07327359
- Testing
- OLX72021
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Olix Pharmaceuticals, Inc.
Androgenetic Alopecia
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK.
- Trial name
- NCT06393452
- Testing
- PP405 0.05% Topical Gel, Topical Vehicle Gel
- Where
- 8 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Pelage Pharmaceuticals, Inc.
Alopecia, Androgenetic, Hair Loss/Baldness
Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia
This study investigated the efficacy of adipose derived stem cell conditioned media (ADSC-CM) combined with minoxidil for hair regeneration therapy in male AGA.
- Trial name
- NCT05296863
- Testing
- Non-concentrated adipose-derived stem cell conditioned media and 5% Minoxidil, Concentrated adipose-derived stem cell conditioned media and 5% Minoxidil
- Where
- Indonesia
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Dr. dr. Lili Legiawati, SpKK(K)
Androgenetic Alopecia (AGA)
Clinical Study of PRP in the Treatment of Androgenetic Alopecia
A study on the therapeutic effect of platelet-rich plasma in the treatment of androgenetic alopecia
- Trial name
- NCT07551271
- Testing
- PRP
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss
Evaluate the ability of Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451099
- Testing
- Autologous cultured dermal cells
- Where
- 6 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia
To Evaluate the Pharmacokinetics and Safety of AD-208
To evaluate pharmacokinetics and safety of AD-208.
- Trial name
- NCT04214808
- Testing
- AD-208, Avodart Soft Capsule 0.5mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Male Pattern Baldness, Androgenetic Alopecia
Assessing the Safety and Efficacy of a Novel Microneedling and Laser Device for Male Pattern Hair Loss
The purpose of this 24-week study is to see if the SAGA-001 device is safe and effective at helping people with male pattern hair loss. Two different device configurations are being explored as part of this study.
- Conditions
- Male Pattern Baldness, Androgenetic Alopecia, Hair Loss/Baldness, Hair Loss
- Trial name
- CS-SAGA-001 (NCT05970809)
- Testing
- SAGA-001 (A), SAGA-001 (B)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 82 people
- Sponsor
- StimuSIL
Male Androgenetic Alopecia
Clinical Trial of Safety and Efficacy of Daily Application of Topical Dutasteride in Men With Androgenic Alopecia.
Alopecia is a disorder that involves the loss of hair from the body. The causes of hair loss can be multiple, but in all cases this loss causes a lot of discomfort to patients for aesthetic and psychological reasons, especially…
- Trial name
- NCT05599243
- Testing
- Dutasteride
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Alopecia, Female Pattern Hair Loss
Minoxidil Response Testing in Females With Female Pattern Hair Loss
The primary purpose of this study is to evaluate the clinical validity of the minoxidil response in-vitro diagnostic kit.
- Trial name
- NCT02206802
- Testing
- 5% minoxidil topical foam
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 300 people
- Sponsor
- Applied Biology, Inc.
Androgenetic Alopecia, Androgenic Alopecia
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss
To demonstrate that the ALRV5XR multi-molecular targeting treatment regimen of a daily shampoo, conditioner, topical serum and oral supplement is superior to placebo in promoting hair growth as assessed by change in hair density…
- Conditions
- Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair
- Trial name
- REBOOT-WOMEN (NCT04450602)
- Testing
- ALRV5XR, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Arbor Life Labs